NO313195B1 - Nye benzimidazolderivater med antihistaminaktivitet og farmasöytisk preparat inneholdende disse - Google Patents
Nye benzimidazolderivater med antihistaminaktivitet og farmasöytisk preparat inneholdende disse Download PDFInfo
- Publication number
- NO313195B1 NO313195B1 NO19972525A NO972525A NO313195B1 NO 313195 B1 NO313195 B1 NO 313195B1 NO 19972525 A NO19972525 A NO 19972525A NO 972525 A NO972525 A NO 972525A NO 313195 B1 NO313195 B1 NO 313195B1
- Authority
- NO
- Norway
- Prior art keywords
- ethyl
- antihistamine
- benzimidazole derivatives
- activity
- new
- Prior art date
Links
- 239000000739 antihistaminic agent Substances 0.000 title claims description 19
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 title claims description 9
- 230000001387 anti-histamine Effects 0.000 title claims description 7
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title claims description 3
- 230000000694 effects Effects 0.000 title description 21
- 239000003814 drug Substances 0.000 title description 4
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical group N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 150000001556 benzimidazoles Chemical class 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 9
- 229940125715 antihistaminic agent Drugs 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 229960004314 bilastine Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 229960000351 terfenadine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- GPTVQTPMFOLLOA-UHFFFAOYSA-N 1-chloro-2-ethoxyethane Chemical compound CCOCCCl GPTVQTPMFOLLOA-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UOUIKYFLNQXAFR-UHFFFAOYSA-N 1h-benzimidazole;piperidine Chemical class C1CCNCC1.C1=CC=C2NC=NC2=C1 UOUIKYFLNQXAFR-UHFFFAOYSA-N 0.000 description 1
- RMALIQMLRXZLAU-UHFFFAOYSA-N 2-[4-[2-[4-[1-(2-hydroxyethyl)benzimidazol-2-yl]piperidin-1-yl]ethyl]phenyl]-2-methylpropanoic acid Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1CCN1CCC(C=2N(C3=CC=CC=C3N=2)CCO)CC1 RMALIQMLRXZLAU-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- HBOGHPAOOWUTLB-UHFFFAOYSA-N 2-piperidin-4-yl-1h-benzimidazole Chemical compound C1CNCCC1C1=NC2=CC=CC=C2N1 HBOGHPAOOWUTLB-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003326 anti-histaminergic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000003126 arrythmogenic effect Effects 0.000 description 1
- 229960004754 astemizole Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002425 cardiocirculatory effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000000306 qrs interval Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09601236A ES2124167B1 (es) | 1996-06-04 | 1996-06-04 | Nuevos derivados del bencimidazol con actividad antihistaminica. |
Publications (3)
Publication Number | Publication Date |
---|---|
NO972525D0 NO972525D0 (no) | 1997-06-03 |
NO972525L NO972525L (no) | 1997-12-05 |
NO313195B1 true NO313195B1 (no) | 2002-08-26 |
Family
ID=8295035
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19972525A NO313195B1 (no) | 1996-06-04 | 1997-06-03 | Nye benzimidazolderivater med antihistaminaktivitet og farmasöytisk preparat inneholdende disse |
NO2011008C NO2011008I2 (no) | 1996-06-04 | 2011-05-24 | Bilastine eller et addisjonssalt derav |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2011008C NO2011008I2 (no) | 1996-06-04 | 2011-05-24 | Bilastine eller et addisjonssalt derav |
Country Status (27)
Country | Link |
---|---|
US (1) | US5877187A (xx) |
EP (1) | EP0818454B1 (xx) |
JP (1) | JP4218991B2 (xx) |
CN (1) | CN1105716C (xx) |
AR (1) | AR008386A1 (xx) |
AT (1) | ATE264317T1 (xx) |
AU (1) | AU725700B2 (xx) |
BR (1) | BR9703276A (xx) |
CA (1) | CA2206754C (xx) |
CZ (1) | CZ289278B6 (xx) |
DE (2) | DE69728608T2 (xx) |
DK (1) | DK0818454T3 (xx) |
ES (1) | ES2124167B1 (xx) |
FR (1) | FR11C0023I2 (xx) |
HR (1) | HRP970307B1 (xx) |
HU (1) | HU227598B1 (xx) |
IN (1) | IN186319B (xx) |
LU (1) | LU91798I2 (xx) |
MX (1) | MXPA97004127A (xx) |
NO (2) | NO313195B1 (xx) |
PL (1) | PL188908B1 (xx) |
PT (1) | PT818454E (xx) |
RU (1) | RU2182150C2 (xx) |
SI (1) | SI0818454T1 (xx) |
TR (1) | TR199700464A3 (xx) |
TW (1) | TW438794B (xx) |
ZA (1) | ZA974893B (xx) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4394799A (en) | 1998-07-01 | 2000-01-24 | Takeda Chemical Industries Ltd. | Retinoid-associated receptor regulators |
HUP0200749A3 (en) | 1998-11-27 | 2003-03-28 | Basf Ag | Substituted benzimidazoles and their use as parp inhibitors and process for their preparation |
ES2151442B1 (es) * | 1999-01-11 | 2001-07-01 | Espanola Prod Quimicos | Nuevo derivado del bencenoetanol. |
US6826561B2 (en) | 2000-05-22 | 2004-11-30 | Broadcom Corporation | Method and apparatus for performing a binary search on an expanded tree |
SK288052B6 (sk) * | 2002-04-19 | 2013-03-01 | Faes Farma, S.A. | Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it |
US20070188330A1 (en) * | 2006-01-24 | 2007-08-16 | Morhard Robert C | System and method for detecting, monitoring, tracking and identifying explosive materials using ID marks |
US7247623B2 (en) * | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
WO2009102155A2 (en) * | 2008-02-12 | 2009-08-20 | Yuhan Corporation | Process for preparation of 2-methyl-2´-phenylpropionic acid derivatives and novel intermediate compounds |
JP2010013472A (ja) * | 2009-09-09 | 2010-01-21 | Faes Farma Sa | 4−[2−[1−(2−エトキシエチル)−1H−ベンズイミダゾール−2−イル]−1−ピペリジニル]エチル]−α,α−ジメチルベンゼノ酢酸の多形体 |
CN102675101B (zh) * | 2012-05-16 | 2014-01-29 | 王蕾 | 2-(4-卤乙基)苯基-2-甲基丙酸酯的制备方法及合成比拉斯汀的方法 |
CZ307500B6 (cs) | 2012-08-15 | 2018-10-24 | Zentiva, K.S. | Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty |
JP6284616B2 (ja) * | 2013-03-15 | 2018-02-28 | ハーキュリーズ・インコーポレーテッドHercules Incorporated | 沈着特性が改善されたパーソナルケア組成物を生成する組成物及び方法 |
CN103214455B (zh) * | 2013-03-30 | 2018-08-31 | 北京万全德众医药生物技术有限公司 | 一种比拉斯汀的制备方法 |
CN103214454A (zh) * | 2013-03-30 | 2013-07-24 | 北京万全德众医药生物技术有限公司 | 一种比拉斯汀晶型及制备方法 |
WO2014188453A2 (en) * | 2013-05-24 | 2014-11-27 | Msn Laboratories Private Limited | Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid |
CN103351380B (zh) * | 2013-06-30 | 2019-01-22 | 北京万全德众医药生物技术有限公司 | 一种制备比拉斯汀的方法 |
CN104447683A (zh) * | 2013-09-12 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 一种稳定的比拉斯汀化合物 |
CN103896915A (zh) * | 2014-04-01 | 2014-07-02 | 中国药科大学 | 苯并咪唑类衍生物、其制备方法及其在医药上的应用 |
EP3040334A1 (en) | 2014-12-29 | 2016-07-06 | Faes Farma, S.A. | New benzimidazole derivatives as antihistamine agents |
CN106349214B (zh) * | 2015-07-13 | 2020-11-03 | 南京长澳医药科技有限公司 | 一种比拉斯汀杂质的制备方法 |
CN107849007B (zh) * | 2015-07-24 | 2024-08-09 | 乌奎玛公司 | 比拉斯汀的晶型及其制备方法 |
CN105272977A (zh) * | 2015-09-19 | 2016-01-27 | 万全万特制药江苏有限公司 | 一种制备比拉斯汀中间体的方法 |
EP3170816A1 (en) | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Supersaturated compositions of benzimidazole compounds |
EP3170817A1 (en) | 2015-11-20 | 2017-05-24 | Faes Farma, S.A. | Co-crystals of benzimidazole compounds |
WO2017167949A1 (en) | 2016-04-01 | 2017-10-05 | Krka, D.D., Novo Mesto | Crystalline forms of bilastine |
WO2017191651A1 (en) * | 2016-05-05 | 2017-11-09 | Msn Laboratories Private Limited, R & D Center | Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof |
CN107365298A (zh) * | 2017-03-14 | 2017-11-21 | 罗欣生物科技(上海)有限公司 | 一种2‑甲基‑2’‑苯基丙酸衍生物的制备方法 |
CN109456316A (zh) * | 2017-09-06 | 2019-03-12 | 万全万特制药江苏有限公司 | 一种比拉斯汀杂质的制备方法 |
ES2813561T3 (es) | 2017-09-07 | 2021-03-24 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica en comprimido que comprende bilastina |
US11642309B2 (en) | 2017-10-16 | 2023-05-09 | Faes Farma, S.A. | Aqueous compositions comprising bilastine and mometasone |
EP3470062B1 (en) | 2017-12-18 | 2020-10-28 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate |
ES2773756R1 (es) | 2017-12-18 | 2021-04-12 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua |
EP3740191B1 (en) | 2018-01-18 | 2021-04-28 | Faes Farma, S.A. | Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent |
CN109081827A (zh) * | 2018-11-06 | 2018-12-25 | 北京天弘天达医药科技股份有限公司 | 一种比拉斯汀的制备方法及应用 |
EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
EP4188339A1 (en) | 2020-07-30 | 2023-06-07 | Faes Farma, S.A. | Decongestant drug delivery system |
CN112110893A (zh) * | 2020-10-28 | 2020-12-22 | 山东齐环医药科技有限公司 | 一种比拉斯汀的制备方法 |
WO2022106923A1 (en) | 2020-11-18 | 2022-05-27 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising an antihistamine compound |
EP4267109A1 (en) | 2020-12-23 | 2023-11-01 | Noucor Health S.A. | A non-micronized bilastine composition |
WO2023156559A1 (en) | 2022-02-17 | 2023-08-24 | Faes Farma, S.A. | Bilastine composition for once-daily parenteral administration |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2048109B1 (es) * | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
ATE363283T1 (de) * | 1992-08-03 | 2007-06-15 | Sepracor Inc | Terfenadin-carboxylat und die behandlung von hautreizung |
ATE230395T1 (de) * | 1993-06-25 | 2003-01-15 | Merrell Pharma Inc | Neue zwischenprodukte für die herstellung von antihistaminschen 4- diphenylmethyl/diphenylmethoxypiperidin-derivat n |
-
1996
- 1996-06-04 ES ES09601236A patent/ES2124167B1/es not_active Expired - Fee Related
-
1997
- 1997-06-03 AU AU24672/97A patent/AU725700B2/en not_active Expired
- 1997-06-03 DE DE69728608T patent/DE69728608T2/de not_active Expired - Lifetime
- 1997-06-03 NO NO19972525A patent/NO313195B1/no not_active IP Right Cessation
- 1997-06-03 SI SI9730652T patent/SI0818454T1/xx unknown
- 1997-06-03 PT PT97500099T patent/PT818454E/pt unknown
- 1997-06-03 HR HR970307A patent/HRP970307B1/xx not_active IP Right Cessation
- 1997-06-03 RU RU97108980/04A patent/RU2182150C2/ru active
- 1997-06-03 CA CA002206754A patent/CA2206754C/en not_active Expired - Lifetime
- 1997-06-03 DE DE122011000006C patent/DE122011000006I1/de active Pending
- 1997-06-03 DK DK97500099T patent/DK0818454T3/da active
- 1997-06-03 AT AT97500099T patent/ATE264317T1/de active
- 1997-06-03 EP EP97500099A patent/EP0818454B1/en not_active Expired - Lifetime
- 1997-06-03 ZA ZA9704893A patent/ZA974893B/xx unknown
- 1997-06-04 US US08/868,743 patent/US5877187A/en not_active Expired - Lifetime
- 1997-06-04 MX MXPA97004127A patent/MXPA97004127A/es active IP Right Grant
- 1997-06-04 HU HU9700997A patent/HU227598B1/hu active Protection Beyond IP Right Term
- 1997-06-04 CZ CZ19971723A patent/CZ289278B6/cs not_active IP Right Cessation
- 1997-06-04 TR TR97/00464A patent/TR199700464A3/tr unknown
- 1997-06-04 BR BR9703276-0A patent/BR9703276A/pt not_active IP Right Cessation
- 1997-06-04 IN IN1498DE1997 patent/IN186319B/en unknown
- 1997-06-04 CN CN97114905A patent/CN1105716C/zh not_active Expired - Lifetime
- 1997-06-04 JP JP16201097A patent/JP4218991B2/ja not_active Expired - Lifetime
- 1997-06-04 PL PL97320358A patent/PL188908B1/pl unknown
- 1997-06-05 AR ARP970102441A patent/AR008386A1/es active IP Right Grant
- 1997-07-22 TW TW086110371A patent/TW438794B/zh not_active IP Right Cessation
-
2011
- 2011-03-22 LU LU91798C patent/LU91798I2/fr unknown
- 2011-05-24 NO NO2011008C patent/NO2011008I2/no unknown
- 2011-07-08 FR FR11C0023C patent/FR11C0023I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO313195B1 (no) | Nye benzimidazolderivater med antihistaminaktivitet og farmasöytisk preparat inneholdende disse | |
DE3005948C2 (xx) | ||
DE3889133T2 (de) | N-Heterocyclische N-(4-Piperidyl)-amide. | |
US5070087A (en) | Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents | |
EP0079545B1 (en) | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same | |
DE60300021T2 (de) | que- | |
TW419477B (en) | Diphenylmethylene piperidine derivatives | |
US20040044004A1 (en) | Calcium channel inhibitors comprising benzhydril spaced from piperazine | |
EP2108648A1 (de) | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel | |
CN114014796A (zh) | 一类依巴斯汀的盐及其制备方法和应用 | |
US5670509A (en) | Tocolytic oxytocin receptor antagonists | |
US6391890B1 (en) | Heterocyclic compounds | |
US20040266784A1 (en) | Calcium channel inhibitors comprising benzhydril spaced from piperazine | |
DE2652201A1 (de) | Benzisothiazolone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeparate | |
US5292745A (en) | Use of 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine derivatives as free radical scavengers | |
IE59434B1 (en) | n-substituted diphenylpiperidines | |
DE69404158T2 (de) | 4-alkylamino-1-phenoxyalkyl piperidine als antiinflammatorische, antiallergische und immunomodulierende wirkstoffe | |
DE60306138T2 (de) | Azaindolylpiperidinderivate als antihistaminika und antiallergika | |
DE60009287T2 (de) | Neuartige isoquinolin-derivate oder salze davon | |
DE60118434T2 (de) | Indolylpiperidinderivate als antihistaminische und antiallergische mittel | |
US5525600A (en) | (Thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides | |
HU193719B (en) | Process for producing antiarrithmic aryloxy-6-/aminoalkyl/-1-pirrolidine- and piperidine-carboxylic acids | |
AU8714991A (en) | 4-acetoxy-piperidine derivatives, process for their preparation and use as a muscarinic m3-receptor antagonist | |
DD296923A5 (de) | Piperidinylbenzimidazoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneipraeperate | |
DE2734270C2 (xx) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: ZILAS; NAT. REG. NO/DATE: 09-6621 20110413; FIRST REG. NO/DATE: IS/1/10/002/01 20100923 Spc suppl protection certif: 2011008 Filing date: 20110524 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: ZILAS; NAT. REG. NO/DATE: 09-6621 20110413; FIRST REG. NO/DATE: IS/1/10/002/01 20100923 Spc suppl protection certif: 2011008 Filing date: 20110524 Extension date: 20220603 |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Spc suppl protection certif: 2011008 |